Perspective Therapeutics, Inc. (CATX) shareholders
Close on Nov 20, 2026Market cap $86.05MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Schultz Michael K | 16,779,075 | 5.90% | 13G (passive) amendment | Dec 31, 2023 |
| Johnson Frances | 16,779,075 | 5.90% | 13G (passive) amendment | Dec 31, 2023 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more | 11,939,753 | 9.90% | 13G (passive) | Feb 2, 2026 |
| Lantheus Alpha Therapy, LLC Joint filing with Lantheus Holdings, Inc. (10.00%), Lantheus Medical Imaging, Inc. (10.00%) | 11,440,513 | 10.00% | 13D (active) amendment | May 15, 2024 |
| Lantheus Holdings, Inc. Joint filing with Lantheus Medical Imaging, Inc. (7.70%), Lantheus Alpha Therapy, LLC (7.70%) | 8,739,011 | 7.70% | 13D (active) amendment | Sep 21, 2026 |
| Chen Yu | 7,915,567 | 6.90% | 13G (passive) | Feb 3, 2026 |
| BlackRock, Inc. | 7,776,940 | 6.80% | 13G (passive) | Jun 30, 2026 |
| Qatar Investment Authority | 7,073,308 | 6.20% | 13G (passive) | Feb 4, 2026 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.50%), Millennium Group Management LLC (5.50%) and 1 more | 6,316,545 | 5.50% | 13G (passive) amendment | Aug 7, 2026 |
| Avidity Partners Management (GP) LLC Joint filing with Avidity Partners Management LP (5.30%), Avidity Capital Partners Fund (GP) LP (5.30%) and 3 more | 6,049,999 | 5.30% | 13G (passive) | Feb 20, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.30%), Israel A. Englander (5.30%) | 6,036,999 | 5.30% | 13G (passive) | Jul 13, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CATX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,494,152 | 8.32% | $32.38M | +4,145,591 | 0.00% |
| TCG Crossover Management, LLC | 7,915,567 | 6.93% | $26.99M | – | 0.65% |
| Commodore Capital LP | 6,336,782 | 5.55% | $21.61M | – | 1.29% |
| Avidity Partners Management LP | 6,299,999 | 5.52% | $21.48M | −5,799,999 | 3.44% |
| State Street Corp | 6,051,771 | 5.30% | $20.64M | +2,919,101 | 0.00% |
| Millennium Management LLC | 4,911,855 | 4.30% | $16.75M | +865,215 | 0.01% |
| Nantahala Capital Management, LLC | 4,650,900 | 4.07% | $15.86M | New | 0.26% |
| Vanguard Capital Management LLC | 4,436,572 | 3.89% | $15.13M | +57,616 | 0.00% |
| Affinity Asset Advisors, LLC | 4,214,582 | 3.69% | $14.37M | +1,050,000 | 0.65% |
| Citadel Advisors LLC | 3,805,739 | 3.33% | $12.98M | +239,235 | 0.00% |
| Spruce Street Capital LP | 3,693,931 | 3.24% | $12.60M | +1,066,824 | 2.47% |
| Balyasny Asset Management L.P. | 3,320,224 | 2.91% | $11.32M | +325,764 | 0.01% |
| Geode Capital Management, LLC | 2,458,673 | 2.15% | $8.39M | +691,713 | 0.00% |
| Morgan Stanley | 1,912,550 | 1.68% | $6.52M | −1,070,792 | 0.00% |
| Goldman Sachs Group Inc | 1,733,078 | 1.52% | $5.91M | +491,262 | 0.00% |
| Nicholson Wealth Management Group, LLC | 1,619,993 | 1.42% | $5.52M | +1,000 | 3.25% |
| Two Sigma Investments, LP | 1,556,451 | 1.36% | $5.31M | +552,977 | 0.00% |
| ADAR1 Capital Management, LLC | 1,210,117 | 1.06% | $4.13M | +460,782 | 0.19% |
| Vanguard Portfolio Management LLC | 1,087,767 | 0.95% | $3.71M | +335,734 | 0.00% |
| Dimensional Fund Advisors LP | 1,074,071 | 0.94% | $3.66M | +623,974 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 130 | 89M | 78.2% | 24 / 60 | 26 / 29 | 21M | 16M |
| Q1 2026 | 136 | 85M | 74.1% | 47 / 41 | 28 / 23 | 58M | 6M |
| Q4 2025 | 115 | 36M | 31.8% | 24 / 31 | 36 / 10 | 7M | 14M |
| Q3 2025 | 103 | 43M | 37.6% | 16 / 31 | 30 / 8 | 6M | 5M |
| Q2 2025 | 95 | 42M | 37.0% | 9 / 38 | 22 / 24 | 7M | 9M |
| Q1 2025 | 110 | 44M | 38.7% | 13 / 34 | 38 / 36 | 5M | 7M |
| Q4 2024 | 134 | 47M | 41.3% | 36 / 48 | 31 / 24 | 15M | 16M |
| Q3 2024 | 126 | 49M | 43.0% | 43 / 47 | 22 / 19 | 19M | 5M |
| Q2 2024 | 103 | 39M | 33.8% | 103 / 0 | 0 / 0 | 39M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
116 funds held CATX in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CATX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,036,281 | 3.54% | $13.76M | 0.13% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,313,065 | 2.90% | $11.30M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,647,335 | 2.32% | $9.03M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,126,721 | 0.99% | $3.28M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,017,864 | 0.89% | $3.47M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 977,879 | 0.86% | $3.33M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 636,237 | 0.56% | $2.17M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 445,775 | 0.39% | $1.76M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 405,058 | 0.35% | $1.60M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 346,808 | 0.30% | $1.18M | 0.08% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 319,770 | 0.28% | $1.26M | 0.01% | May 31, 2026 |
| Vanguard Health Care Index Fund | 288,380 | 0.25% | $1.14M | 0.01% | May 31, 2026 |
| U.S. Small Cap Portfolio | 269,566 | 0.24% | $784.44K | 0.00% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 258,600 | 0.23% | $1.02M | 0.02% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 254,330 | 0.22% | $740.10K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Johan M. Spoor | Chief Executive Officer, Director | 134,683 | 0.12% | Nov 12, 2026 |
| Markus Puhlmann | Chief Medical Officer | 178,542 | 0.16% | Nov 13, 2026 |
| Jonathan Robert Hunt | Chief Accounting Officer | 59,800 | 0.05% | Mar 4, 2026 |
| Joel Sendek | Chief Financial Officer | – | – | Sep 5, 2025 |
| Juan Graham | Chief Financial Officer | 35,354 | 0.03% | Apr 1, 2025 |
| Robert F. Williamson III | Director | 183,744 | 0.16% | Nov 19, 2026 |
| Frank Morich | Director | 30,000 | 0.03% | Nov 17, 2026 |
| Lori A. Woods | Director | 212,017 | 0.19% | Nov 16, 2026 |
| Maria E. Martinez | Director | – | – | Mar 4, 2026 |
| Heidi Henson | Director | 25,975 | 0.02% | Mar 4, 2026 |
| Lantheus Alpha Therapy, LLC | 10% owner | 11,273,364 | 9.88% | Sep 8, 2026 |
| Lantheus Holdings, Inc. | 10% owner | 11,521,296 | 10.09% | Sep 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert F. Williamson III Director | Nov 18, 2026 | Buy | +15,000 | $0.80 | $12.00K | 68,473 |
| Robert F. Williamson III Director | Nov 17, 2026 | Buy | +25,000 | $0.84 | $20.95K | 53,473 |
| Frank Morich Director | Nov 16, 2026 | Buy | +15,000 | $0.94 | $14.05K | 30,000 |
| Frank Morich Director | Nov 12, 2026 | Buy | +15,000 | $1.00 | $14.96K | 15,000 |
| Robert F. Williamson III Director | Nov 12, 2026 | Buy | +6,289 | $0.84 | $5.27K | 115,271 |
| Robert F. Williamson III Director | Nov 12, 2026 | Buy | +18,609 | $0.84 | $15.63K | 28,473 |
| Lori A. Woods Director | Nov 12, 2026 | Buy | +23,750 | $0.84 | $20.04K | 28,557 |
| Markus Puhlmann Chief Medical Officer | Nov 12, 2026 | Buy | +35,000 | $0.84 | $29.56K | 178,542 |
| Markus Puhlmann Chief Medical Officer | Nov 11, 2026 | Buy | +6,000 | $0.83 | $4.98K | 143,542 |
| Johan M. Spoor Chief Executive Officer, Director | Nov 11, 2026 | Buy | +47,000 | $0.81 | $37.94K | 106,383 |
| Lantheus Alpha Therapy, LLC 10% owner | Sep 4, 2026 | Sale | −167,149 | $3.15 | $526.52K | 11,273,364 |
| Lantheus Alpha Therapy, LLC 10% owner | Sep 3, 2026 | Sale | −80,783 | $3.11 | $251.24K | 11,440,513 |
| Lantheus Holdings, Inc. 10% owner | Sep 2, 2026 | Sale | −42,129 | $3.11 | $131.02K | 11,521,296 |
| Lantheus Alpha Therapy, LLC 10% owner | Sep 1, 2026 | Sale | −35,769 | $3.12 | $111.60K | 11,563,425 |
| Lantheus Holdings, Inc. 10% owner | Sep 1, 2026 | Sale | −35,769 | $3.12 | $111.60K | 11,563,425 |
| Lantheus Alpha Therapy, LLC 10% owner | Aug 31, 2026 | Sale | −78,145 | $3.14 | $245.38K | 11,599,194 |
| Lantheus Holdings, Inc. 10% owner | Aug 31, 2026 | Sale | −78,145 | $3.14 | $245.38K | 11,599,194 |
| Jonathan Robert Hunt Chief Accounting Officer | Nov 13, 2025 | Buy | +11,000 | $2.03 | $22.33K | 59,800 |
| Robert F. Williamson III Director | Nov 12, 2025 | Buy | +9,498 | $2.10 | $19.95K | 9,864 |
| Lori A. Woods Director | Mar 31, 2025 | Buy | +23,475 | $2.13 | $50.00K | 183,460 |
| Robert F. Williamson III Director | Mar 31, 2025 | Buy | +38,145 | $2.14 | $81.63K | 108,982 |
| Juan Graham Chief Financial Officer | Mar 28, 2025 | Buy | +33,333 | $2.25 | $75.00K | 35,354 |
| Robert F. Williamson III Director | Mar 28, 2025 | Buy | +22,192 | $2.27 | $50.38K | 70,837 |
| Johan M. Spoor Chief Executive Officer, Director | Mar 28, 2025 | Buy | +22,026 | $2.24 | $49.34K | 59,383 |
| Johan M. Spoor Chief Executive Officer, Director | Mar 28, 2025 | Buy | +4,650 | $2.21 | $10.28K | 4,650 |
| Heidi Henson Director | Dec 4, 2024 | Buy | +25,975 | $3.85 | $100.00K | 25,975 |
| Johan M. Spoor CEO, Director | Dec 4, 2024 | Buy | +8,000 | $3.77 | $30.16K | 36,257 |
| Jonathan Robert Hunt Chief Financial Officer | Nov 25, 2024 | Buy | +29 | $3.94 | $114 | 36,400 |
| Jonathan Robert Hunt Chief Financial Officer | Nov 25, 2024 | Buy | +400 | $3.55 | $1.42K | 36,371 |
| Jonathan Robert Hunt Chief Financial Officer | Nov 25, 2024 | Buy | +2,400 | $3.60 | $8.64K | 38,800 |
| Jonathan Robert Hunt Chief Financial Officer | Nov 25, 2024 | Buy | +10,000 | $3.88 | $38.80K | 48,800 |
| Robert F. Williamson III Director | Nov 25, 2024 | Buy | +2,619 | $3.67 | $9.61K | 430,058 |
| Robert F. Williamson III Director | Nov 25, 2024 | Buy | +3,647 | $3.62 | $13.20K | 427,439 |
| Johan M. Spoor CEO, Director | Nov 25, 2024 | Buy | +5,400 | $3.80 | $20.52K | 5,400 |
| Johan M. Spoor CEO, Director | Nov 25, 2024 | Buy | +14,500 | $3.78 | $54.81K | 152,072 |
| Johan M. Spoor CEO, Director | Nov 25, 2024 | Buy | +6,600 | $3.80 | $25.08K | 66,600 |
| Jonathan Robert Hunt Chief Financial Officer | Jun 17, 2024 | Buy | +1,800 | $9.82 | $17.68K | 35,971 |
| Lori A. Woods Director | Jun 14, 2024 | Buy | +83 | $10.80 | $896 | 159,985 |
| Lori A. Woods Director | Jun 14, 2024 | Buy | +4,504 | $10.90 | $49.09K | 159,902 |
| Johan M. Spoor CEO, Director | Jun 13, 2024 | Buy | +100,000 | $1.17 | $117.00K | 137,572 |
| Lori A. Woods Director | Jun 3, 2024 | Buy | +34,246 | $1.46 | $50.00K | 1,553,984 |
| Robert F. Williamson III Director | May 31, 2024 | Buy | +55,000 | $1.38 | $75.90K | 423,792 |
| Jonathan Robert Hunt Chief Financial Officer | May 31, 2024 | Buy | +12,000 | $1.40 | $16.80K | 341,716 |
| Jonathan Robert Hunt Chief Financial Officer | May 31, 2024 | Buy | +13,006 | $1.40 | $18.21K | 329,716 |
| Robert F. Williamson III Director | May 29, 2024 | Buy | +18,656 | $1.34 | $25.00K | 368,792 |
| Robert F. Williamson III Director | May 29, 2024 | Buy | +11,375 | $1.32 | $15.02K | 350,136 |
| Mark John Austin VP Finance/Prin Fin&Acct Offic | Apr 23, 2024 | Option exercise | +30,000 | $0.36 | $10.80K | 84,030 |
| Lantheus Alpha Therapy, LLC 10% owner | Mar 6, 2024 | Buy | +60,431,039 | $0.95 | $57.41M | 116,773,394 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +3,500 | $0.70 | $2.45K | 338,761 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +18,579 | $0.71 | $13.19K | 230,134 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +5,127 | $0.71 | $3.64K | 235,261 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +57,121 | $0.71 | $40.56K | 292,382 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +42,879 | $0.72 | $30.87K | 335,261 |
| Robert F. Williamson III Director | Jan 29, 2024 | Buy | +4,031 | $0.64 | $2.58K | 190,320 |
| Robert F. Williamson III Director | Jan 29, 2024 | Buy | +21,235 | $0.64 | $13.59K | 211,555 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +14,850 | $0.61 | $9.06K | 102,776 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +12,250 | $0.61 | $7.47K | 87,926 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +50,000 | $0.54 | $27.00K | 186,289 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +25,000 | $0.55 | $13.75K | 136,289 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +8,513 | $0.59 | $5.02K | 111,289 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Perspective Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 695,239 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark John Austin affiliate | Sep 12, 2024 | 2,500 | $39.50K | Sep 12, 2024 | Option Exercise and Sell All |
See a number that looks wrong?